CAR-T Cells in the Treatment of Malignant Hematological Tumors

Not Applicable

Recruiting

• Conditions: Leukemia, T-Cell; Multiple Myeloma; Lymphoma, B-Cell; Leukemia, B-cell
• Interventions: Biological: CAR-T

• Registration Number: NCT05619861
• Lead Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Brief Summary

To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors

Detailed Description

Main research objective: To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors. Secondary research objective: To investigate the efficacy and cytodynamic characteristics of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors

Study Timeline

• Study Start: 2020-04-27
• Status Verified: 2022-11
• Study First Submitted: 2022-11-09
• Study First Submitted QC: 2022-11-09
• Last Update Submitted: 2022-11-09
• Study First Posted: 2022-11-17
• Last Update Posted: 2022-11-17
• Primary Completion: 2023-01-26
• Study Completion: 2023-12-26

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CAR-T	CAR-T	Autologous CAR-T cells, intravenous infusion, infusion dose 0.1-3 × 106CAR-T cells/kg

Primary Outcome Measures

Name	Time	Method
Safety: Incidence and severity of adverse events	24 months post CAR-T cells infusion	The incidence and severity of adverse events and adverse reactions from infusion to withdrawal or before the safety follow-up period

Trial Locations

Locations (1)

Cangzhou People's Hospital; 🇨🇳 Cangzhou, Hebei, China